Detecting High-Dose Methotrexate-Induced Brain Changes in Pediatric and Young Adult Cancer Survivors Using [ 18 F]FDG PET/MRI: A Pilot Study

Significant improvements in treatments for children with cancer have resulted in a growing population of childhood cancer survivors who may face long-term adverse outcomes. Here, we aimed to diagnose high-dose methotrexate-induced brain injury on [ F]FDG PET/MRI and correlate the results with cognit...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of Nuclear Medicine 2024-06, Vol.65 (6), p.864-871
Hauptverfasser: Baratto, Lucia, Singh, Shashi B, Williams, Sharon E, Spunt, Sheri L, Rosenberg, Jarrett, Adams, Lisa, Suryadevara, Vidyani, Iv, Michael, Daldrup-Link, Heike
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 871
container_issue 6
container_start_page 864
container_title Journal of Nuclear Medicine
container_volume 65
creator Baratto, Lucia
Singh, Shashi B
Williams, Sharon E
Spunt, Sheri L
Rosenberg, Jarrett
Adams, Lisa
Suryadevara, Vidyani
Iv, Michael
Daldrup-Link, Heike
description Significant improvements in treatments for children with cancer have resulted in a growing population of childhood cancer survivors who may face long-term adverse outcomes. Here, we aimed to diagnose high-dose methotrexate-induced brain injury on [ F]FDG PET/MRI and correlate the results with cognitive impairment identified by neurocognitive testing in pediatric cancer survivors. In this prospective, single-center pilot study, 10 children and young adults with sarcoma ( = 5), lymphoma ( = 4), or leukemia ( = 1) underwent dedicated brain [ F]FDG PET/MRI and a 2-h expert neuropsychologic evaluation on the same day, including the Wechsler Abbreviated Scale of Intelligence, second edition, for intellectual functioning; Delis-Kaplan Executive Function System (DKEFS) for executive functioning; and Wide Range Assessment of Memory and Learning, second edition (WRAML), for verbal and visual memory. Using PMOD software, we measured the SUV , cortical thickness, mean cerebral blood flow (CBF ), and mean apparent diffusion coefficient of 3 different cortical regions (prefrontal cortex, cingulate gyrus, and hippocampus) that are routinely involved during the above-specified neurocognitive testing. Standardized scores of different measures were converted to scores. Pairs of multivariable regression models (one for scores < 0 and one for scores > 0) were fitted for each brain region, imaging measure, and test score. Heteroscedasticity regression models were used to account for heterogeneity in variances between brain regions and to adjust for clustering within patients. The regression analysis showed a significant correlation between the SUV of the prefrontal cortex and cingulum and DKEFS-sequential tracking (DKEFS-TM4) scores ( = 0.003 and = 0.012, respectively). The SUV of the hippocampus did not correlate with DKEFS-TM4 scores ( = 0.111). The SUV for any evaluated brain regions did not correlate significantly with WRAML-visual memory (WRAML-VIS) scores. CBF showed a positive correlation with SUV ( = 0.56, = 0.01). The CBF of the cingulum, hippocampus, and prefrontal cortex correlated significantly with DKEFS-TM4 (all < 0.001). In addition, the hippocampal CBF correlated significantly with negative WRAML-VIS scores ( = 0.003). High-dose methotrexate-induced brain injury can manifest as a reduction in glucose metabolism and blood flow in specific brain areas, which can be detected with [ F]FDG PET/MRI. The SUV and CBF of the prefrontal cortex and cingulum can serve as q
doi_str_mv 10.2967/jnumed.123.266760
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11149594</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3064695446</sourcerecordid><originalsourceid>FETCH-LOGICAL-c277t-510b1ac0eb5a6922008be8502439a0bae42b358edcede3ee7acaa4073b1cc9703</originalsourceid><addsrcrecordid>eNpVkd1qGzEQhUVpSNwkD9CbIuj1OtJqpd3tTXHsODEk1OTnopQitNqJLWNLqX5M8w596Mg4De3VzDBnzhz4EPpIybBsRX22smkD_ZCWbFgKUQvyDg0oZ7zgeXqPBoQKWnBO-BH6EMKKECKapjlER6zhNactG6A_E4igo7ELfGUWy2LiAuAbiEsXPfxWEYqZ7ZOGHp97ZSweL5VdQMC5nUNvVPRGY2V7_N2l7DHq0zrisbIaPL5Lfmu2zgf8EHYPfmDa4OnP6eQSzy_uz25uZ1_wCM_N2kV8F1P_fIIOHtU6wOlrPUYP04v78VVx_e1yNh5dF7qs61hwSjqqNIGOK9GWJSFNBw0nZcVaRToFVdkx3kCfYwMDqJVWqiI166jWbU3YMfq6931K3WYns9GrtXzyZqP8s3TKyP831izlwm0lpbRqeVtlh8-vDt79ShCiXLnkbQ4tGRGVaHlViayie5X2LgQPj28vKJE7gnJPUGaCck8w33z6N9vbxV9k7AVohZkq</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3064695446</pqid></control><display><type>article</type><title>Detecting High-Dose Methotrexate-Induced Brain Changes in Pediatric and Young Adult Cancer Survivors Using [ 18 F]FDG PET/MRI: A Pilot Study</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Baratto, Lucia ; Singh, Shashi B ; Williams, Sharon E ; Spunt, Sheri L ; Rosenberg, Jarrett ; Adams, Lisa ; Suryadevara, Vidyani ; Iv, Michael ; Daldrup-Link, Heike</creator><creatorcontrib>Baratto, Lucia ; Singh, Shashi B ; Williams, Sharon E ; Spunt, Sheri L ; Rosenberg, Jarrett ; Adams, Lisa ; Suryadevara, Vidyani ; Iv, Michael ; Daldrup-Link, Heike</creatorcontrib><description>Significant improvements in treatments for children with cancer have resulted in a growing population of childhood cancer survivors who may face long-term adverse outcomes. Here, we aimed to diagnose high-dose methotrexate-induced brain injury on [ F]FDG PET/MRI and correlate the results with cognitive impairment identified by neurocognitive testing in pediatric cancer survivors. In this prospective, single-center pilot study, 10 children and young adults with sarcoma ( = 5), lymphoma ( = 4), or leukemia ( = 1) underwent dedicated brain [ F]FDG PET/MRI and a 2-h expert neuropsychologic evaluation on the same day, including the Wechsler Abbreviated Scale of Intelligence, second edition, for intellectual functioning; Delis-Kaplan Executive Function System (DKEFS) for executive functioning; and Wide Range Assessment of Memory and Learning, second edition (WRAML), for verbal and visual memory. Using PMOD software, we measured the SUV , cortical thickness, mean cerebral blood flow (CBF ), and mean apparent diffusion coefficient of 3 different cortical regions (prefrontal cortex, cingulate gyrus, and hippocampus) that are routinely involved during the above-specified neurocognitive testing. Standardized scores of different measures were converted to scores. Pairs of multivariable regression models (one for scores &lt; 0 and one for scores &gt; 0) were fitted for each brain region, imaging measure, and test score. Heteroscedasticity regression models were used to account for heterogeneity in variances between brain regions and to adjust for clustering within patients. The regression analysis showed a significant correlation between the SUV of the prefrontal cortex and cingulum and DKEFS-sequential tracking (DKEFS-TM4) scores ( = 0.003 and = 0.012, respectively). The SUV of the hippocampus did not correlate with DKEFS-TM4 scores ( = 0.111). The SUV for any evaluated brain regions did not correlate significantly with WRAML-visual memory (WRAML-VIS) scores. CBF showed a positive correlation with SUV ( = 0.56, = 0.01). The CBF of the cingulum, hippocampus, and prefrontal cortex correlated significantly with DKEFS-TM4 (all &lt; 0.001). In addition, the hippocampal CBF correlated significantly with negative WRAML-VIS scores ( = 0.003). High-dose methotrexate-induced brain injury can manifest as a reduction in glucose metabolism and blood flow in specific brain areas, which can be detected with [ F]FDG PET/MRI. The SUV and CBF of the prefrontal cortex and cingulum can serve as quantitative measures for detecting executive functioning problems. Hippocampal CBF could also be useful for monitoring memory problems.</description><identifier>ISSN: 0161-5505</identifier><identifier>EISSN: 1535-5667</identifier><identifier>EISSN: 2159-662X</identifier><identifier>DOI: 10.2967/jnumed.123.266760</identifier><identifier>PMID: 38575193</identifier><language>eng</language><publisher>United States: Society of Nuclear Medicine</publisher><subject>Adolescent ; Adult ; Blood flow ; Brain ; Brain - diagnostic imaging ; Brain - drug effects ; Brain injury ; Cancer ; Cancer Survivors ; Cerebral blood flow ; Child ; Children ; Cingulum ; Clinical Investigation ; Clustering ; Cognition ; Cognitive ability ; Correlation ; Diffusion coefficient ; Evaluation ; Executive function ; Female ; Fluorine isotopes ; Fluorodeoxyglucose F18 ; Glucose metabolism ; Head injuries ; Heterogeneity ; Hippocampus ; Humans ; Intelligence ; Leukemia ; Lymphoma ; Magnetic Resonance Imaging ; Male ; Memory ; Methotrexate ; Methotrexate - adverse effects ; Methotrexate - therapeutic use ; Multimodal Imaging ; Neuroimaging ; Pediatrics ; Pilot Projects ; Positron emission ; Positron emission tomography ; Prefrontal cortex ; Prospective Studies ; Regression analysis ; Regression models ; Sarcoma ; Survival ; Traumatic brain injury ; Young Adult ; Young adults</subject><ispartof>Journal of Nuclear Medicine, 2024-06, Vol.65 (6), p.864-871</ispartof><rights>2024 by the Society of Nuclear Medicine and Molecular Imaging.</rights><rights>Copyright Society of Nuclear Medicine Jun 1, 2024</rights><rights>2024 by the Society of Nuclear Medicine and Molecular Imaging. 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c277t-510b1ac0eb5a6922008be8502439a0bae42b358edcede3ee7acaa4073b1cc9703</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38575193$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Baratto, Lucia</creatorcontrib><creatorcontrib>Singh, Shashi B</creatorcontrib><creatorcontrib>Williams, Sharon E</creatorcontrib><creatorcontrib>Spunt, Sheri L</creatorcontrib><creatorcontrib>Rosenberg, Jarrett</creatorcontrib><creatorcontrib>Adams, Lisa</creatorcontrib><creatorcontrib>Suryadevara, Vidyani</creatorcontrib><creatorcontrib>Iv, Michael</creatorcontrib><creatorcontrib>Daldrup-Link, Heike</creatorcontrib><title>Detecting High-Dose Methotrexate-Induced Brain Changes in Pediatric and Young Adult Cancer Survivors Using [ 18 F]FDG PET/MRI: A Pilot Study</title><title>Journal of Nuclear Medicine</title><addtitle>J Nucl Med</addtitle><description>Significant improvements in treatments for children with cancer have resulted in a growing population of childhood cancer survivors who may face long-term adverse outcomes. Here, we aimed to diagnose high-dose methotrexate-induced brain injury on [ F]FDG PET/MRI and correlate the results with cognitive impairment identified by neurocognitive testing in pediatric cancer survivors. In this prospective, single-center pilot study, 10 children and young adults with sarcoma ( = 5), lymphoma ( = 4), or leukemia ( = 1) underwent dedicated brain [ F]FDG PET/MRI and a 2-h expert neuropsychologic evaluation on the same day, including the Wechsler Abbreviated Scale of Intelligence, second edition, for intellectual functioning; Delis-Kaplan Executive Function System (DKEFS) for executive functioning; and Wide Range Assessment of Memory and Learning, second edition (WRAML), for verbal and visual memory. Using PMOD software, we measured the SUV , cortical thickness, mean cerebral blood flow (CBF ), and mean apparent diffusion coefficient of 3 different cortical regions (prefrontal cortex, cingulate gyrus, and hippocampus) that are routinely involved during the above-specified neurocognitive testing. Standardized scores of different measures were converted to scores. Pairs of multivariable regression models (one for scores &lt; 0 and one for scores &gt; 0) were fitted for each brain region, imaging measure, and test score. Heteroscedasticity regression models were used to account for heterogeneity in variances between brain regions and to adjust for clustering within patients. The regression analysis showed a significant correlation between the SUV of the prefrontal cortex and cingulum and DKEFS-sequential tracking (DKEFS-TM4) scores ( = 0.003 and = 0.012, respectively). The SUV of the hippocampus did not correlate with DKEFS-TM4 scores ( = 0.111). The SUV for any evaluated brain regions did not correlate significantly with WRAML-visual memory (WRAML-VIS) scores. CBF showed a positive correlation with SUV ( = 0.56, = 0.01). The CBF of the cingulum, hippocampus, and prefrontal cortex correlated significantly with DKEFS-TM4 (all &lt; 0.001). In addition, the hippocampal CBF correlated significantly with negative WRAML-VIS scores ( = 0.003). High-dose methotrexate-induced brain injury can manifest as a reduction in glucose metabolism and blood flow in specific brain areas, which can be detected with [ F]FDG PET/MRI. The SUV and CBF of the prefrontal cortex and cingulum can serve as quantitative measures for detecting executive functioning problems. Hippocampal CBF could also be useful for monitoring memory problems.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Blood flow</subject><subject>Brain</subject><subject>Brain - diagnostic imaging</subject><subject>Brain - drug effects</subject><subject>Brain injury</subject><subject>Cancer</subject><subject>Cancer Survivors</subject><subject>Cerebral blood flow</subject><subject>Child</subject><subject>Children</subject><subject>Cingulum</subject><subject>Clinical Investigation</subject><subject>Clustering</subject><subject>Cognition</subject><subject>Cognitive ability</subject><subject>Correlation</subject><subject>Diffusion coefficient</subject><subject>Evaluation</subject><subject>Executive function</subject><subject>Female</subject><subject>Fluorine isotopes</subject><subject>Fluorodeoxyglucose F18</subject><subject>Glucose metabolism</subject><subject>Head injuries</subject><subject>Heterogeneity</subject><subject>Hippocampus</subject><subject>Humans</subject><subject>Intelligence</subject><subject>Leukemia</subject><subject>Lymphoma</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Memory</subject><subject>Methotrexate</subject><subject>Methotrexate - adverse effects</subject><subject>Methotrexate - therapeutic use</subject><subject>Multimodal Imaging</subject><subject>Neuroimaging</subject><subject>Pediatrics</subject><subject>Pilot Projects</subject><subject>Positron emission</subject><subject>Positron emission tomography</subject><subject>Prefrontal cortex</subject><subject>Prospective Studies</subject><subject>Regression analysis</subject><subject>Regression models</subject><subject>Sarcoma</subject><subject>Survival</subject><subject>Traumatic brain injury</subject><subject>Young Adult</subject><subject>Young adults</subject><issn>0161-5505</issn><issn>1535-5667</issn><issn>2159-662X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkd1qGzEQhUVpSNwkD9CbIuj1OtJqpd3tTXHsODEk1OTnopQitNqJLWNLqX5M8w596Mg4De3VzDBnzhz4EPpIybBsRX22smkD_ZCWbFgKUQvyDg0oZ7zgeXqPBoQKWnBO-BH6EMKKECKapjlER6zhNactG6A_E4igo7ELfGUWy2LiAuAbiEsXPfxWEYqZ7ZOGHp97ZSweL5VdQMC5nUNvVPRGY2V7_N2l7DHq0zrisbIaPL5Lfmu2zgf8EHYPfmDa4OnP6eQSzy_uz25uZ1_wCM_N2kV8F1P_fIIOHtU6wOlrPUYP04v78VVx_e1yNh5dF7qs61hwSjqqNIGOK9GWJSFNBw0nZcVaRToFVdkx3kCfYwMDqJVWqiI166jWbU3YMfq6931K3WYns9GrtXzyZqP8s3TKyP831izlwm0lpbRqeVtlh8-vDt79ShCiXLnkbQ4tGRGVaHlViayie5X2LgQPj28vKJE7gnJPUGaCck8w33z6N9vbxV9k7AVohZkq</recordid><startdate>20240601</startdate><enddate>20240601</enddate><creator>Baratto, Lucia</creator><creator>Singh, Shashi B</creator><creator>Williams, Sharon E</creator><creator>Spunt, Sheri L</creator><creator>Rosenberg, Jarrett</creator><creator>Adams, Lisa</creator><creator>Suryadevara, Vidyani</creator><creator>Iv, Michael</creator><creator>Daldrup-Link, Heike</creator><general>Society of Nuclear Medicine</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>4T-</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P64</scope><scope>5PM</scope></search><sort><creationdate>20240601</creationdate><title>Detecting High-Dose Methotrexate-Induced Brain Changes in Pediatric and Young Adult Cancer Survivors Using [ 18 F]FDG PET/MRI: A Pilot Study</title><author>Baratto, Lucia ; Singh, Shashi B ; Williams, Sharon E ; Spunt, Sheri L ; Rosenberg, Jarrett ; Adams, Lisa ; Suryadevara, Vidyani ; Iv, Michael ; Daldrup-Link, Heike</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c277t-510b1ac0eb5a6922008be8502439a0bae42b358edcede3ee7acaa4073b1cc9703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Blood flow</topic><topic>Brain</topic><topic>Brain - diagnostic imaging</topic><topic>Brain - drug effects</topic><topic>Brain injury</topic><topic>Cancer</topic><topic>Cancer Survivors</topic><topic>Cerebral blood flow</topic><topic>Child</topic><topic>Children</topic><topic>Cingulum</topic><topic>Clinical Investigation</topic><topic>Clustering</topic><topic>Cognition</topic><topic>Cognitive ability</topic><topic>Correlation</topic><topic>Diffusion coefficient</topic><topic>Evaluation</topic><topic>Executive function</topic><topic>Female</topic><topic>Fluorine isotopes</topic><topic>Fluorodeoxyglucose F18</topic><topic>Glucose metabolism</topic><topic>Head injuries</topic><topic>Heterogeneity</topic><topic>Hippocampus</topic><topic>Humans</topic><topic>Intelligence</topic><topic>Leukemia</topic><topic>Lymphoma</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Memory</topic><topic>Methotrexate</topic><topic>Methotrexate - adverse effects</topic><topic>Methotrexate - therapeutic use</topic><topic>Multimodal Imaging</topic><topic>Neuroimaging</topic><topic>Pediatrics</topic><topic>Pilot Projects</topic><topic>Positron emission</topic><topic>Positron emission tomography</topic><topic>Prefrontal cortex</topic><topic>Prospective Studies</topic><topic>Regression analysis</topic><topic>Regression models</topic><topic>Sarcoma</topic><topic>Survival</topic><topic>Traumatic brain injury</topic><topic>Young Adult</topic><topic>Young adults</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Baratto, Lucia</creatorcontrib><creatorcontrib>Singh, Shashi B</creatorcontrib><creatorcontrib>Williams, Sharon E</creatorcontrib><creatorcontrib>Spunt, Sheri L</creatorcontrib><creatorcontrib>Rosenberg, Jarrett</creatorcontrib><creatorcontrib>Adams, Lisa</creatorcontrib><creatorcontrib>Suryadevara, Vidyani</creatorcontrib><creatorcontrib>Iv, Michael</creatorcontrib><creatorcontrib>Daldrup-Link, Heike</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Docstoc</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of Nuclear Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Baratto, Lucia</au><au>Singh, Shashi B</au><au>Williams, Sharon E</au><au>Spunt, Sheri L</au><au>Rosenberg, Jarrett</au><au>Adams, Lisa</au><au>Suryadevara, Vidyani</au><au>Iv, Michael</au><au>Daldrup-Link, Heike</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Detecting High-Dose Methotrexate-Induced Brain Changes in Pediatric and Young Adult Cancer Survivors Using [ 18 F]FDG PET/MRI: A Pilot Study</atitle><jtitle>Journal of Nuclear Medicine</jtitle><addtitle>J Nucl Med</addtitle><date>2024-06-01</date><risdate>2024</risdate><volume>65</volume><issue>6</issue><spage>864</spage><epage>871</epage><pages>864-871</pages><issn>0161-5505</issn><eissn>1535-5667</eissn><eissn>2159-662X</eissn><abstract>Significant improvements in treatments for children with cancer have resulted in a growing population of childhood cancer survivors who may face long-term adverse outcomes. Here, we aimed to diagnose high-dose methotrexate-induced brain injury on [ F]FDG PET/MRI and correlate the results with cognitive impairment identified by neurocognitive testing in pediatric cancer survivors. In this prospective, single-center pilot study, 10 children and young adults with sarcoma ( = 5), lymphoma ( = 4), or leukemia ( = 1) underwent dedicated brain [ F]FDG PET/MRI and a 2-h expert neuropsychologic evaluation on the same day, including the Wechsler Abbreviated Scale of Intelligence, second edition, for intellectual functioning; Delis-Kaplan Executive Function System (DKEFS) for executive functioning; and Wide Range Assessment of Memory and Learning, second edition (WRAML), for verbal and visual memory. Using PMOD software, we measured the SUV , cortical thickness, mean cerebral blood flow (CBF ), and mean apparent diffusion coefficient of 3 different cortical regions (prefrontal cortex, cingulate gyrus, and hippocampus) that are routinely involved during the above-specified neurocognitive testing. Standardized scores of different measures were converted to scores. Pairs of multivariable regression models (one for scores &lt; 0 and one for scores &gt; 0) were fitted for each brain region, imaging measure, and test score. Heteroscedasticity regression models were used to account for heterogeneity in variances between brain regions and to adjust for clustering within patients. The regression analysis showed a significant correlation between the SUV of the prefrontal cortex and cingulum and DKEFS-sequential tracking (DKEFS-TM4) scores ( = 0.003 and = 0.012, respectively). The SUV of the hippocampus did not correlate with DKEFS-TM4 scores ( = 0.111). The SUV for any evaluated brain regions did not correlate significantly with WRAML-visual memory (WRAML-VIS) scores. CBF showed a positive correlation with SUV ( = 0.56, = 0.01). The CBF of the cingulum, hippocampus, and prefrontal cortex correlated significantly with DKEFS-TM4 (all &lt; 0.001). In addition, the hippocampal CBF correlated significantly with negative WRAML-VIS scores ( = 0.003). High-dose methotrexate-induced brain injury can manifest as a reduction in glucose metabolism and blood flow in specific brain areas, which can be detected with [ F]FDG PET/MRI. The SUV and CBF of the prefrontal cortex and cingulum can serve as quantitative measures for detecting executive functioning problems. Hippocampal CBF could also be useful for monitoring memory problems.</abstract><cop>United States</cop><pub>Society of Nuclear Medicine</pub><pmid>38575193</pmid><doi>10.2967/jnumed.123.266760</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0161-5505
ispartof Journal of Nuclear Medicine, 2024-06, Vol.65 (6), p.864-871
issn 0161-5505
1535-5667
2159-662X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11149594
source MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Adolescent
Adult
Blood flow
Brain
Brain - diagnostic imaging
Brain - drug effects
Brain injury
Cancer
Cancer Survivors
Cerebral blood flow
Child
Children
Cingulum
Clinical Investigation
Clustering
Cognition
Cognitive ability
Correlation
Diffusion coefficient
Evaluation
Executive function
Female
Fluorine isotopes
Fluorodeoxyglucose F18
Glucose metabolism
Head injuries
Heterogeneity
Hippocampus
Humans
Intelligence
Leukemia
Lymphoma
Magnetic Resonance Imaging
Male
Memory
Methotrexate
Methotrexate - adverse effects
Methotrexate - therapeutic use
Multimodal Imaging
Neuroimaging
Pediatrics
Pilot Projects
Positron emission
Positron emission tomography
Prefrontal cortex
Prospective Studies
Regression analysis
Regression models
Sarcoma
Survival
Traumatic brain injury
Young Adult
Young adults
title Detecting High-Dose Methotrexate-Induced Brain Changes in Pediatric and Young Adult Cancer Survivors Using [ 18 F]FDG PET/MRI: A Pilot Study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T15%3A31%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Detecting%20High-Dose%20Methotrexate-Induced%20Brain%20Changes%20in%20Pediatric%20and%20Young%20Adult%20Cancer%20Survivors%20Using%20%5B%2018%20F%5DFDG%20PET/MRI:%20A%20Pilot%20Study&rft.jtitle=Journal%20of%20Nuclear%20Medicine&rft.au=Baratto,%20Lucia&rft.date=2024-06-01&rft.volume=65&rft.issue=6&rft.spage=864&rft.epage=871&rft.pages=864-871&rft.issn=0161-5505&rft.eissn=1535-5667&rft_id=info:doi/10.2967/jnumed.123.266760&rft_dat=%3Cproquest_pubme%3E3064695446%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3064695446&rft_id=info:pmid/38575193&rfr_iscdi=true